PerkinElmer reports ‘good progress’ in second quarter

PerkinElmer chairman and chief executive officer Robert Friel has praised the “good progress” made by the company following the publication of its second quarter financial report.

The science company saw its revenue jump by 14 per cent year-on-year during the three-month period, reaching a total of $497.8 million (315.8 million pounds), with growth reflected across its human health and environmental health business units.

This strong performance meant that rates of earnings per share for the quarter exceeded initial guidance, while profit levels were also up.

As a result of this, PerkinElmer has been able to increase its financial forecast for the full year, with Mr Friel hailing the company’s “broad-based strength”.

He added: “We have made very good progress against our strategic priorities of increasing the growth profile of the company through leveraging adjacent markets and geographic expansion, as well as establishing a framework to drive higher profitability.”

This comes after PerkinElmer last week announced that it is purchasing the in vivo molecular imaging technology specialist VisEn Medical, a move which will expand its preclinical research offering.